Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roche

Miniature organs on chips could revolutionize health-care research

To understand how bodies work, medical researchers and scientists have created mini models of organs, called organoids. This field of scientific research has had profound impacts on biological discovery and pharmaceutical development.

The Conversation

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Investors Business Daily

Roivant higher as Vivek Ramaswamy-found firm sells bowel disease drug for $7.1 billion

Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance

Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.

Investors Business Daily

Patients in England will be first to access seven-minute cancer treatment jab

NHS is first health system to offer injection to hundreds of patients which will cut treatment times by up to three quarters

The Guardian - UK

Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22%

Roche accidentally published positive interim results from a lung cancer treatment study, which boosted shares of rivals Iteos and Arcus.

Investors Business Daily

Scottish firm working towards ‘transformative’ early blood test for Alzheimer’s

Scottish Brain Sciences is collaborating with Roche Diagnostics on the project.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Sales Of TG Therapeutics' New Product Doubled — Here's Why Shares Halved

Sales of TG Therapeutics' highly anticipated multiple sclerosis drug, Briumvi, missed forecasts on Tuesday and TGTX stock plummeted.

Investors Business Daily

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

The Guardian - UK

Roche Could Take A Page Out Of Merck's Playbook. Why Roivant Surged.

Roche is in discussions to buy a stomach-disease treatment from Roivant for around $7 billion. The report sent ROIV stock surging Friday.

Investors Business Daily

How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg

Roche unveiled positive results Thursday for a rival to TG Therapeutics' infusion for multiple sclerosis patients, and TGTX stock crashed.

Investors Business Daily

Roche and ZS partner to set up dedicated centre in Chennai

Roche, a biopharmaceutical company and ZS a global management consulting and technology firm, on Friday announced the inauguration of a Business Operations Center for Advanced Analytics and Business Insights in Chennai.

The Hindu

'The dirty disease' – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

The Conversation

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Arcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug Class

Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

Cycling News

Tiffany Cromwell, Tasman Nankervis win Australia’s Nannup Gravel World Series race

Mark Chong second ahead of Nicolas Roche in men's category, Cassia Boglio and Courtney Sherwell complete women’s podium

Investors Business Daily

Drug Heavyweights GSK, Roche Topple As Covid Weighs On Sales Growth

GSK leaned on vaccines while Roche relied on pharmaceutical sales to outplay Covid declines. But shares of both fell Tuesday.

Investors Business Daily

Trillions In Biotech Stock Gains Trace Back To This Financier

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket

Bayer stock surged to an eight-month high Wednesday after the company named former Roche exec Bill Anderson as its new chief executive.

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Investors Business Daily

Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?

Merck is navigating a looming patent expiration for its blockbuster Keytruda. Now, Merck stock is trading at its highest point in decades.

The Street

Morningstar's List of Best-to-Own Healthcare Stocks

'Healthcare is a sector that generally holds steady no matter what is happening in the economy,' the research firm said.

StockNews.com

4 Stocks Under $30 to Buy Right Now

While a recession in 2023 looks inevitable amid lingering macro headwinds, experts believe it to be mild. Moreover, amid high hopes for a Santa Claus rally, quality stocks Stellantis (STLA), Albertsons Companies (ACI), Poseida Therapeutics (PSTX), and Civeo (CVEO) could be ideal buys under $30 now. Keep reading….

Investors Business Daily

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

The Independent UK

Vet's lawsuit blaming antimalarial drug for psychosis tossed

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.